Content MOMT 306 (Winter 2018 Section 08) 306 Management 306 Final Memo Write a
ID: 351913 • Letter: C
Question
Content MOMT 306 (Winter 2018 Section 08) 306 Management 306 Final Memo Write a business memo responding to one of the following prompts: RU-32 You're the CEO of a global pharmaceutical company. After decades of work (and the investment of hundreds of millions of dollars), your scientists have come up with a major breakthrough. Your new drug, RU-32, is a low-cost anti-diabetic medication that dramatically stabilizes insulin levels.If approved, your company will own the patent on a drug worth billions of dollars. However, during Phase Ill clinical trials, unexpected complications arose, and approval by the FDA is now unlikely. Without FDA approval, you cannot sell RU-32 in the U.S. and most developed countries. However, other countries-primarily developing countries-will allow you to market the drug without U.s FDA approval. You must choose whether to stop all development and cancel the program, or proceed with manufacturing for sale to citizens of developing countries Inform the Board of Directors of your decision. Write a memo explaining your position and your reasons.Be specific and use detailed examples to support your main points. Press-Enterprise A statistic taken from the Press-Enterprise states that the average American worker spends about 1.8 hours of every eight hour work day on non-work activities (e g. personal phone calls, internet surfing, etc.) Estimates suggest this lack of productivity costs American business hundreds of milions of dollars annually, but workers say focusing eight hours a day strictly on work-related business is unreasonable and impossible considering we work more hours than ever before. Additionally, workers argue they need to schedule appointments and daily activities when businesses are open, In your opinion, which side makes a stronger case? Write a persuasive memo to your business arguing one side. Be specific and use detailed examples to support your main points 20 F3 1 F4 FS F6 F7 F9 F1OExplanation / Answer
Answer:
Memorandum To: Board of Directors
From : CEO
Date : xx/yy/zzzz
Subject: Decision on moving forward on launching our new drug RU-32 to the market, after Phase-III clinical trial issue
The purpose of this memo is to inform the board of director, regarding my decision on moving forwad with lauching and sales process, for our new breakthrough drug RU-32, which is for diabetics patients.
Since we all know that our drug had faced a unexpected complication, in phase III clinical trail, it's creates a difficult situation for us to obtain a approval from FDA, in any time soon. Eventhough we can own a patent, without FDA approval we can't sell our drugs in most of the developed countries.
Although we can't procure FDA approval, at this point of time, we can't stop process. since, we have invested huge of time and multi million dollars in phase I and II . Moreover, again a solid good amount of time and money is required for taking up the phase III trial again.
It's well know that, we can use the drugs at emergency situtation, which it's being on phase -III trail. Also, some of the developing countries doesn't need or look for an FDA approval, to sell our product. Our anti -diabetic medication RU-32 will create a breakthrough in medical history, if we recticy the issue aroused during phase III and it's possible we continue to do the research.
So it's good for us to move forward with the research to rectify and pass the phase III and IV clinical trials. Since, we are an global pharmaceuticals company, we know that diabectic patients are high in numbers in the developing and under developed countries . We can sell our product in the company's existing markets, which doesn't require a FDA approval, for our anti diabectic medication RU-32.
With all the above valid points, it is to inform the board of directors that, I suggest to continue our program without stoping it.
If you are still in need of addtional information, I shall be happy ro have a meet with the Board of Directors.
Related Questions
drjack9650@gmail.com
Navigate
Integrity-first tutoring: explanations and feedback only — we do not complete graded work. Learn more.